LIVIVO - Search results -

Search results

Result 1 - 10 of total 41

Search options

Article ; Online: Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.

Reda, Manon / Macaire, Pauline / Bellio, Hélène / Uwer, Lionel / Ilie, Silvia / Lorgis, Véronique / Hennequin, Audrey / Ladoire, Sylvain / Rederstorff, Emilie / Fumoleau, Pierre / Isambert, Nicolas / Bonnin, Nathalie / You, Benoit / Freyer, Gilles / Desmoulins, Isabelle / Schmitt, Antonin

Cancer chemotherapy and pharmacology

2022 Volume 89, Issue 2, Page(s) 197–208

Abstract: Background: Granulocyte colony-stimulating factors (G-CSF) are commonly given to limit chemotherapy-induced neutropenia, but, in case of weekly chemotherapy such as eribulin, their administration schedules remain empirical.: Objectives: This ... ...

Abstract	Background: Granulocyte colony-stimulating factors (G-CSF) are commonly given to limit chemotherapy-induced neutropenia, but, in case of weekly chemotherapy such as eribulin, their administration schedules remain empirical. Objectives: This pharmacokinetic/pharmacodynamic (PK/PD) study was conducted to establish the effect of different G-CSF regimens on neutropenia's incidence for patients treated by eribulin, to propose an optimal G-CSF dosing schedule. Methods: A population PK/PD model was developed to describe absolute neutrophil counts' (ANC) time course in 87 cancer patients receiving eribulin. The structural model considered ANC dynamics, neutropenic effect of eribulin and stimulating effect of G-CSF. Final model estimates were used to calculate neutropenia's incidence following different G-CSF dosing schedules for 1000 virtual subjects. Results: The final model successfully described most of the ANC time course for all patients. Simulations showed that a single G-CSF administration 48 h after each eribulin injection reduced the risk of severe neutropenia from 29.7 to 5.2%. Five days of G-CSF only after the second eribulin injection or no G-CSF administration induces similar incidence of neutropenia. Conclusion: Simulations showed a single G-CSF administration 48 h after the end of each eribulin injection seems to be the optimal schedule to reduce eribulin-induced neutropenia. However, the new administration scheme should be tested in real life to evaluate its pertinence. Trial registration: Eudract 2015-001753-32, 2015/01/26.
MeSH term(s)	Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Breast Neoplasms/drug therapy ; Drug Administration Schedule ; Female ; Furans/administration & dosage ; Furans/adverse effects ; Furans/pharmacokinetics ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Ketones/administration & dosage ; Ketones/adverse effects ; Ketones/pharmacokinetics ; Middle Aged ; Models, Biological ; Neutropenia/chemically induced ; Neutropenia/prevention & control
Chemical Substances	Antineoplastic Agents ; Furans ; Ketones ; Granulocyte Colony-Stimulating Factor (143011-72-7) ; eribulin (LR24G6354G)
Language	English
Publishing date	2022-01-08
Publishing country	Germany
Document type	Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	6820-2
ISSN	1432-0843 ; 0344-5704 ; 0943-9404
ISSN (online)	1432-0843
ISSN	0344-5704 ; 0943-9404
DOI	10.1007/s00280-021-04395-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1420: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.

Jacot, William / Lusque, Amélie / Vicier, Cécile / Mailliez, Audrey / de La Motte Rouge, Thibault / Cabel, Luc / Levy, Christelle / Patsouris, Anne / Desmoulins, Isabelle / Uwer, Lionel / Thery, Jean-Christophe / Robain, Mathieu / Caron, Olivier / Tredan, Olivier / Filleron, Thomas / Frenel, Jean-Sébastien / Delaloge, Suzette

British journal of cancer

2022 Volume 127, Issue 11, Page(s) 1963–1973

Abstract: Background: The efficacy and added benefit of platinum-based chemotherapy (PtCT) for metastatic breast cancer (MBC) remain unclear in patients with and without germline BRCA1 or BRCA2 mutations (gBRCA1/2m and gBRCA1/2wt, respectively).: Methods: We ... ...

Abstract	Background: The efficacy and added benefit of platinum-based chemotherapy (PtCT) for metastatic breast cancer (MBC) remain unclear in patients with and without germline BRCA1 or BRCA2 mutations (gBRCA1/2m and gBRCA1/2wt, respectively). Methods: We selected from the French national real-world multicentre ESME cohort (2008-2016) all patients with HER2-negative MBC with known gBRCA1/2 status at first-line chemotherapy initiation. Using multivariable Cox models, we compared the outcome (progression-free (PFS) and overall survival (OS)) of first-line PtCT and non-PtCT regimens based on the patients' gBRCA1/2 status and tumour subtype. Results: Patients who received PtCT had more aggressive tumour features. In the multivariable analysis, first-line PtCT was associated with better adjusted PFS and OS in gBRCA1/2m carriers (N = 300), compared with non-PtCT (HR 0.54, 95% CI 0.4-0.73, P < 0.001, and HR 0.70, 95% CI 0.49-0.99, P = 0.047, respectively). Conversely, outcomes were similar in gBRCA1/2wt patients (N = 922) treated with PtCT and non-PtCT, whatever the tumour subtype. Landmark analyses at months 3 and 6 post treatment initiation supported these results. Conclusions: In this pre-PARP inhibitor real-world cohort, PFS and OS were better after PtCT than non-PtCT in patients with gBRCA1/2m, but not in those with gBRCA1/2wt. These results emphasise the need of early gBRCA1/2 testing in patients with MBC. Clinical trial number: NCT03275311.
MeSH term(s)	Female ; Humans ; Antineoplastic Agents/therapeutic use ; BRCA1 Protein/genetics ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Germ Cells ; Mutation ; Platinum/therapeutic use
Chemical Substances	Antineoplastic Agents ; BRCA1 Protein ; BRCA1 protein, human ; Platinum (49DFR088MY)
Language	English
Publishing date	2022-10-07
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80075-2
ISSN	1532-1827 ; 0007-0920
ISSN (online)	1532-1827
ISSN	0007-0920
DOI	10.1038/s41416-022-02003-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.142: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.

François-Martin, Hélène / Lardy-Cléaud, Audrey / Pistilli, Barbara / Levy, Christelle / Diéras, Véronique / Frenel, Jean-Sébastien / Guiu, Séverine / Mouret-Reynier, Marie-Ange / Mailliez, Audrey / Eymard, Jean-Christophe / Petit, Thierry / Ung, Mony / Desmoulins, Isabelle / Augereau, Paule / Bachelot, Thomas / Uwer, Lionel / Debled, Marc / Ferrero, Jean-Marc / Clatot, Florian /

Goncalves, Anthony / Chevrot, Michael / Chabaud, Sylvie / Cottu, Paul

Cancers

2023 Volume 15, Issue 4

Abstract: Everolimus is the first oral targeted therapy widely used in advanced HR+/HER2- breast cancer. We sought to evaluate the impact of everolimus-based therapy on overall survival in the ESME-MBC database, a national metastatic breast cancer cohort that ... ...

Abstract	Everolimus is the first oral targeted therapy widely used in advanced HR+/HER2- breast cancer. We sought to evaluate the impact of everolimus-based therapy on overall survival in the ESME-MBC database, a national metastatic breast cancer cohort that collects retrospective data using clinical trial-like methodology including quality assessments. We compared 1693 patients having received everolimus to 5928 patients not exposed to everolimus in the same period. Overall survival was evaluated according to treatment line, and a propensity score with the inverse probability of treatment weighting method was built to adjust for differences between groups. Crude and landmark overall survival analyses were all compatible with a benefit from everolimus-based therapy. Adjusted hazard ratios for overall survival were 0.34 (95% CI: 0.16-0.72,
Language	English
Publishing date	2023-02-13
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15041191
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.

Courtinard, Coralie / Gourgou, Sophie / Jacot, William / Carton, Matthieu / Guérin, Olivier / Vacher, Laure / Bertaut, Aurélie / Le Deley, Marie-Cécile / Pérol, David / Marino, Patricia / Levy, Christelle / Uwer, Lionel / Perrocheau, Geneviève / Schiappa, Renaud / Bachelot, Florence / Parent, Damien / Breton, Mathias / Petit, Thierry / Filleron, Thomas /

Loeb, Agnès / Pélissier, Simone Mathoulin / Robain, Mathieu / Delaloge, Suzette / Bellera, Carine

BMC medicine

2023 Volume 21, Issue 1, Page(s) 87

Abstract: Background: Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains ... ...

Abstract	Background: Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains scarce regarding the degree of association between PFS and OS. Our study aimed to describe the individual-level association between real-world PFS (rwPFS) and OS according to first-line treatment in female patients with mBC managed in real-world setting for each BC subtype (defined by status for both hormone-receptor [HR] expression and HER2 protein expression/gene amplification). Methods: We extracted data from the ESME mBC database (NCT03275311) which gathers deidentified data from consecutive patients managed in 18 French Comprehensive Cancer Centers. Adult women diagnosed with mBC between 2008 and 2017 were included. Endpoints (PFS, OS) were described using the Kaplan-Meier method. Individual-level associations between rwPFS and OS were estimated using the Spearman's correlation coefficient. Analyses were conducted by tumor subtype. Results: 20,033 women were eligible. Median age was 60.0 years. Median follow-up duration was 62.3 months. Median rwPFS ranged from 6.0 months (95% CI 5.8-6.2) for HR-/HER2 - subtype to 13.3 months (36% CI 12.7-14.3) for HR + /HER2 + subtype. Correlation coefficients were highly variable across subtypes and first-line (L1) treatments. Among patients with HR - /HER2 - mBC, correlation coefficients ranged from 0.73 to 0.81, suggesting a strong rwPFS/OS association. For HR + /HER2 + mBC patients, the individual-level associations were weak to strong with coefficients ranging from 0.33 to 0.43 for monotherapy and from 0.67 to 0.78 for combined therapies. Conclusions: Our study provides comprehensive information on individual-level association between rwPFS and OS for L1 treatments in mBC women managed in real-life practice. Our results could be used as a basis for future research dedicated to surrogate endpoint candidates.
MeSH term(s)	Adult ; Female ; Humans ; Middle Aged ; Breast Neoplasms/drug therapy ; Progression-Free Survival ; Databases, Factual ; Gene Expression
Language	English
Publishing date	2023-03-08
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2131669-7
ISSN	1741-7015 ; 1741-7015
ISSN (online)	1741-7015
ISSN	1741-7015
DOI	10.1186/s12916-023-02754-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.

Le Du, Fanny / Carton, Matthieu / Bachelot, Thomas / Saghatchian, Mahasti / Pistilli, Barbara / Brain, Etienne / Loirat, Delphine / Vanlemmens, Laurence / Vermeulin, Thomas / Emile, George / Gonçalves, Anthony / Ung, Mony / Robert, Marie / Jaffre, Anne / Desmoulins, Isabelle / Jouannaud, Christelle / Uwer, Lionel / Marc Ferrero, Jean / Mouret-Reynier, Marie-Ange /

Jacot, William / Chevrot, Michaël / Delaloge, Suzette / Diéras, Véronique

The oncologist

2023 Volume 28, Issue 10, Page(s) e867–e876

Abstract: Background: Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as whether (neo)adjuvant anti-HER2 treatments impact the patterns of recurrence and outcomes of HER2- ... ...

Abstract	Background: Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as whether (neo)adjuvant anti-HER2 treatments impact the patterns of recurrence and outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC). We aimed to assess this in the large multicenter ESME real-world database. Patients and methods: We examined the characteristics and outcomes (overall survival (OS) and progression-free survival under first-line treatment (PFS1)) of HER2+ patients with MBC from the French ESME program with recurrent disease, as a function of the previous receipt of adjuvant trastuzumab. Multivariable analyses used Cox models adjusted for baseline demographic, prognostic factors, adjuvant treatment received, and disease-free interval. Results: Two thousand one hundred and forty-three patients who entered the ESME cohort between 2008 and 2017 had a recurrent HER2+ MBC. Among them, 56% had received (neo)adjuvant trastuzumab and 2.5% another anti-HER2 in this setting. Patients pre-exposed to trastuzumab were younger, had a lower disease-free interval, more HR-negative disease and more metastatic sites. While the crude median OS appeared inferior in patients exposed to adjuvant trastuzumab, as compared to those who did not (37.2 (95%CI 34.4-40.3) versus 53.5 months (95% CI: 47.6-60.1)), this difference disappeared in the multivariable model (HR = 1.05, 95%CI 0.91-1.22). The same figures were observed for PFS1. Conclusions: Among patients with relapsed HER2+ MBC, the receipt of adjuvant trastuzumab did not independently predict for worse outcomes when adjusted to other prognostic factors.
MeSH term(s)	Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Disease-Free Survival ; Progression-Free Survival ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Trastuzumab/therapeutic use ; Chemotherapy, Adjuvant
Chemical Substances	Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
Language	English
Publishing date	2023-08-17
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1093/oncolo/oyad137
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.

Breast cancer (Tokyo, Japan)

2023 Volume 30, Issue 2, Page(s) 329–341

Abstract: Background: More than 10% of HER2-positive metastatic breast cancer (mBC) will develop Central Nervous System (CNS) metastases as first and isolated site of relapse on trastuzumab and pertuzumab first-line therapy. However, few clinical data are ... ...

Abstract	Background: More than 10% of HER2-positive metastatic breast cancer (mBC) will develop Central Nervous System (CNS) metastases as first and isolated site of relapse on trastuzumab and pertuzumab first-line therapy. However, few clinical data are available to guide the best strategy in this setting. Methods: Patients experiencing isolated CNS progression on trastuzumab and pertuzumab first-line therapy were retrospectively identified from the French Epidemiological Strategy and Medical Economics (ESME) real-life database between 2008 and 2016. Results: Among 995 patients treated with first-line trastuzumab and pertuzumab for HER2-positive mBC, 132 patients (13%) experienced isolated CNS progression with a median time of 12 months after mBC diagnosis. Twelves patients did not receive any treatment and were excluded from the analysis. Among the 120 patients considered, 76 (63%) received CNS-directed local therapy, 73 (60%) continued trastuzumab and pertuzumab, whereas 47 (39%) started another systemic treatment. After a median follow-up of 21 months, there was no difference in progression-free survival for patient who continued trastuzumab-pertuzumab or switched to another systemic treatment. In multivariate analysis, trastuzumab-pertuzumab continuation was associated with longer OS (HR 0,28 IC 95%: 0,14-0,54 p < 0,001). mOS was not reached (95% 37.6-NE) and was 23.2 months (95% CI 15.5-53.6) in patients who continued trastuzumab and pertuzumab therapy and in patients who switched for another systemic therapy, respectively. Conclusion: In this real-life cohort, trastuzumab-pertuzumab continuation after local treatment for isolated CNS progression did not negatively impact PFS and OS. Prospective trials and assessment of new strategies are warranted in this specific situation.
MeSH term(s)	Humans ; Female ; Trastuzumab/therapeutic use ; Breast Neoplasms/pathology ; Retrospective Studies ; Prospective Studies ; Receptor, ErbB-2 ; Neoplasm Recurrence, Local/drug therapy ; Central Nervous System/pathology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Treatment Outcome
Chemical Substances	Trastuzumab (P188ANX8CK) ; pertuzumab (K16AIQ8CTM) ; Receptor, ErbB-2 (EC 2.7.10.1)
Language	English
Publishing date	2023-01-11
Publishing country	Japan
Document type	Journal Article
ZDB-ID	2052429-8
ISSN	1880-4233 ; 1340-6868
ISSN (online)	1880-4233
ISSN	1340-6868
DOI	10.1007/s12282-022-01427-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5536: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.

Grinda, Thomas / Antoine, Alison / Jacot, William / Cottu, Paul-Henri / de la Motte Rouge, Thibault / Frenel, Jean-Sébastien / Mailliez, Audrey / Dalenc, Florence / Goncalves, Anthony / Clatot, Florian / Mouret Reynier, Marie-Ange / Levy, Christelle / Ferrero, Jean-Marc / Desmoulins, Isabelle / Uwer, Lionel / Petit, Thierry / Jouannaud, Christelle / Arnedos, Monica / Chevrot, Michaël /

Courtinard, Coralie / Tredan, Olivier / Brain, Etienne / Pérol, David / Pistilli, Barbara / Delaloge, Suzette

European journal of cancer (Oxford, England : 1990)

2023 Volume 189, Page(s) 112935

Abstract: Background: Early metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation requiring urgent characterisation and handling. Epidemio- ... ...

Abstract	Background: Early metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation requiring urgent characterisation and handling. Epidemio-Strategy-Medico-Economical-Metastatic Breast Cancer (ESME-MBC) database, a multicenter, national, observational cohort (NCT03275311) provides recent data on this entity. Methods: All ESME patients diagnosed between 2008 and 2020 with mTNBC occurring as a relapse after a systemic neoadjuvant/adjuvant taxane and/or anthracycline-based chemotherapy were included. Early relapses were defined by a metastatic diagnosis up to 12 months of the end of neo/adjuvant A/T chemotherapy. We assessed overall survival (OS) and progression-free-survival under first-line treatment (PFS1) by early versus late relapse (≥12 months). Results: Patients with early relapse (N = 881, 46%) were younger and had a larger tumour burden at primary diagnosis than those with late relapses (N = 1045). Early relapse rates appeared stable over time. Median OS was 10.1 months (95% CI 9.3-10.9) in patients with early relapse versus 17.1 months (95% CI 15.7-18.2) in those with late relapse (adjusted hazard-ratio (aHR): 1.92 (95% CI 1.73-2.13); p < 0.001). The median PFS1 was respectively 3.1 months (95% CI 2.9-3.4) and 5.3 months (95% CI 5.1-5.8); (aHR: 1.66; [95% CI 1.50-1.83]; p < 0.001). Among early relapsed patients, a higher number of metastatic sites, visceral disease but not treatment types, were independently associated with a poorer OS. Conclusion: These real-world data provide strong evidence on the dismal prognosis, higher treatment resistance and major unmet medical need associated with early relapsed mTNBC. Database registration: clinicaltrials.gov Identifier NCT032753.
MeSH term(s)	Humans ; Female ; Breast Neoplasms/pathology ; Triple Negative Breast Neoplasms/drug therapy ; Neoplasm Recurrence, Local/drug therapy ; Progression-Free Survival ; Antibiotics, Antineoplastic ; Prognosis ; Chronic Disease ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemical Substances	Antibiotics, Antineoplastic
Language	English
Publishing date	2023-06-07
Publishing country	England
Document type	Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't ; Legislation
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2023.05.023
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾

Article ; Online: Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.

JAMA network open

2022 Volume 5, Issue 9, Page(s) e2231170

Abstract: Importance: ERBB2-low (ie, ERBB2 immunohistochemistry score of 1+ or 2+ in the absence of ERBB2 gene amplification) breast cancer (BC) is a new entity, with emerging dedicated treatments. Little is known about its prognosis and response to conventional ... ...

Abstract	Importance: ERBB2-low (ie, ERBB2 immunohistochemistry score of 1+ or 2+ in the absence of ERBB2 gene amplification) breast cancer (BC) is a new entity, with emerging dedicated treatments. Little is known about its prognosis and response to conventional therapy compared with ERBB2-zero breast tumors (ie, those with an immunohistochemistry score of 0). Objective: To compare the outcomes for patients with ERBB2-low metastatic BC (MBC) with those of patients with ERBB2-zero MBC. Design, setting, and participants: This cohort study was conducted from the Epidemiological Strategy and Medical Economics MBC platform and included patients with MBC treated between 2008 and 2016 in 18 French comprehensive cancer centers. The data analysis was conducted from July 16, 2020, to April 1, 2022. Main outcomes and measures: The main outcome was overall survival (OS), and the secondary outcome was progression-free survival under first-line treatments (PFS1). Results: The median (range) age was 60.0 (22.0-103.0) years. Among 15 054 patients with MBC, 4671 (31%) had ERBB2-low MBC and 10 383 (69%) had ERBB2-zero MBC. The proportion of ERBB2-low cancers was higher among patients with hormone receptor-positive MBC than those with hormone receptor-negative disease (4083 patients [33.0%] vs 588 patients [21.0%]). With a median follow-up of 49.5 months (95% CI, 48.6-50.4 months), the median OS of the ERBB2-low group was 38.0 months (95% CI, 36.4-40.5 months) compared with 33.9 months (95% CI, 32.9-34.9 months) for the ERBB2-zero group (P < .001). After adjustment for age, visceral metastases, number of metastatic sites, de novo disease, period of care, and hormone receptor status, patients with ERBB2-low MBC had slightly better OS compared with patients with ERBB2-zero MBC (adjusted hazard ratio, 0.95; 95% CI, 0.91-0.99; P = .02). In contrast, PFS1 did not differ by ERBB2 status (adjusted hazard ratio, 0.99; 95% CI, 0.95-1.02; P = .45). No significant differences in OS and PFS1 were observed in multivariate analyses by hormone receptor status and types of frontline treatment. Conclusions and relevance: In this large cohort study, patients with ERBB2-low MBC had a slightly better OS than those with completely ERBB2-zero tumors, but identical PFS1, which could help guide treatment selection.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/pathology ; Cohort Studies ; Female ; Hormones ; Humans ; Middle Aged ; Prognosis ; Receptor, ErbB-2 ; Retrospective Studies ; Young Adult
Chemical Substances	Hormones ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
Language	English
Publishing date	2022-09-01
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2574-3805
ISSN (online)	2574-3805
DOI	10.1001/jamanetworkopen.2022.31170
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Real-world evidence of the management and prognosis of young women (⩽40 years) with

Mallet, Amélie / Lusque, Amélie / Levy, Christelle / Pistilli, Barbara / Brain, Etienne / Pasquier, David / Debled, Marc / Thery, Jean Christophe / Gonçalves, Anthony / Desmoulins, Isabelle / De La Motte Rouge, Thibault / Faure, Christelle / Ferrero, Jean Marc / Eymard, Jean Christophe / Mouret-Reynier, Marie Ange / Patsouris, Anne / Cottu, Paul / Dalenc, Florence / Petit, Thierry /

Payen, Olivier / Uwer, Lionel / Guiu, Séverine / Frenel, Jean Sébastien

Therapeutic advances in medical oncology

2022 Volume 14, Page(s) 17588359211070362

Abstract: Background: Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues. : Methods: We evaluated management of women aged ⩽40 years with : Results: Of the 4524 women included, 598 ( ... ...

Abstract	Background: Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues. Methods: We evaluated management of women aged ⩽40 years with Results: Of the 4524 women included, 598 (13%) were ⩽40 years. Median age at MBC diagnosis was 36 years (range = 20-40). Compared with women aged 41-69 years, young women had more grade III tumours (49% Conclusion: De novo
Language	English
Publishing date	2022-01-21
Publishing country	England
Document type	Journal Article
ZDB-ID	2503443-1
ISSN	1758-8359 ; 1758-8340
ISSN (online)	1758-8359
ISSN	1758-8340
DOI	10.1177/17588359211070362
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database.

Carausu, Marcela / Carton, Matthieu / Cabel, Luc / Patsouris, Anne / Levy, Christelle / Verret, Benjamin / Pasquier, David / Debled, Marc / Gonçalves, Anthony / Desmoulins, Isabelle / Lecouillard, Isabelle / Bachelot, Thomas / Ferrero, Jean-Marc / Eymard, Jean-Christophe / Mouret-Reynier, Marie-Ange / Chevrot, Michaël / De Maio, Eleonora / Uwer, Lionel / Frenel, Jean-Sébastien /

Leheurteur, Marianne / Petit, Thierry / Darlix, Amélie / Bozec, Laurence

Therapeutic advances in medical oncology

2022 Volume 14, Page(s) 17588359221077082

Abstract: Background: As a result of progress in diagnosis and treatment, there is a growing prevalence of metastatic breast cancer (MBC) with isolated CNS metastases. This study describes the largest-to-date real-life cohort of this clinical setting and compares ...

Abstract	Background: As a result of progress in diagnosis and treatment, there is a growing prevalence of metastatic breast cancer (MBC) with isolated CNS metastases. This study describes the largest-to-date real-life cohort of this clinical setting and compares it to other clinical presentations. Methods: We retrospectively analysed the French Epidemiological Strategy and Medical Economics (ESME) MBC database including patients who initiated treatment for MBC between 2008 and 2016. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Descriptive statistics and multivariate Cox model were used. Results: Of 22,266 patients, 647 (2.9%) and 929 (4.2%) patients had isolated first-site CNS metastases or combined with extra-CNS metastases, with longer OS for the group with isolated CNS metastases (16.9 Conclusions: Patients with isolated CNS metastases at MBC diagnosis represent a distinct population for which the role of systemic therapy needs to be further investigated in prospective studies.
Language	English
Publishing date	2022-02-26
Publishing country	England
Document type	Journal Article
ZDB-ID	2503443-1
ISSN	1758-8359 ; 1758-8340
ISSN (online)	1758-8359
ISSN	1758-8340
DOI	10.1177/17588359221077082
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Your last searches

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito